Multiple splicing variants of the estrogen receptor are present in individual human breast tumors

https://doi.org/10.1016/S0960-0760(96)00120-3Get rights and content

Abstract

Transcript variants of the estrogen receptor (ER) were investigated in 109 primary breast tumors using reverse transcription-polymerase chain reaction (RT-PCR) and primers allowing analysis of each internal exon. A high incidence of different ER variants was observed, each individual tumor often manifesting multiple variants coexisting with corresponding wildtype (wt) ER. These variants, by sequence analysis confirmed to represent exon splicing deletions, included ERΔE2 (found in 41% of the tumors examined), ERΔE3 (74%), ERΔE4 (72%), ERΔE5 (66%), and ERΔE7 (88%). No evidence of transcripts lacking exon 6 was found, although a ERΔE5,7 variant manifesting simultaneous deletion of exons 5 and 7 was observed. The presence of specific ER variants was not significantly correlated to the status of ER and progesterone receptor (PgR) protein expression, as assessed by routine analysis, although a trend towards a higher incidence of ERΔE3 and increased expression of ERΔE7 in ER + /PgR- tumors was observed, suggesting a dominant inhibitory effect on normal ER function to be involved. Moreover, ERΔE4 was more common in ER+ tumors, possibly due to a cytoplasmic sequestring of this variant lacking a nuclear localization sequence. The presence of ER variants was not associated to clinicopathological variables, and equally frequent in tumors from patients having recurred or remained recurrence-free during adjuvant tamoxifen therapy. In conclusion, although ER splicing variants are abundant in breast cancer, the present study provides no evidence for a direct role of these ER variants in tumor development and tamoxifen resistance. It remains possible, however, that minor cell clones within the tumor, undetected by analysis of tumor homogenates, displaying extreme difference in content of ER variants, could be selected for during therapy or metastasis.

References (28)

  • S.A.W. Fuqua et al.

    Estrogen receptor mutations in breast cancer

    J. Cell. Biochem.

    (1993)
  • R.J. Miksicek

    Steroid receptor variants and their potential role in cancer

    Semin. Cancer Biol.

    (1994)
  • D.P. McDonnell et al.

    Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors

    Semin. Cancer Biol.

    (1994)
  • S.A.W. Fuqua et al.

    Variant human breast tumor estrogen receptor with constitutive transcriptional activity

    Cancer Res.

    (1991)
  • Cited by (67)

    • Sex-specific effects of 17β-estradiol and dihydrotestosterone (DHT) on growth plate chondrocytes are dependent on both ERα and ERβ and require palmitoylation to translocate the receptors to the plasma membrane

      2021, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
      Citation Excerpt :

      In many cells, the receptors coexist either as homodimers or as heterodimers [6], but the subcellular distribution of the two receptors does not quite overlap. A number of variant transcripts have been described for both ERα and ERβ [7]. Several of the variant transcripts of the primary ERα and ERβ pre-mRNA retain the same reading frame as the full-length transcript.

    • Steroidal pheromones and their potential target sites in the vomeronasal organ

      2019, Steroids
      Citation Excerpt :

      It is possible that the receptor is outside the membrane and the binding to the steroid causes an effect via a second messenger and opening of ion channels. For some steroid receptors like estrogen receptors different splicing variants have been described [91,92]. It is likely that splicing variants have different affinities to the same ligand.

    • MicroRNA-135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth

      2015, Molecular Oncology
      Citation Excerpt :

      However, AR also regulates a distinct set of genes in the recurrent form of PCa compared to the hormone dependent form of PCa, often in a tissue specific manner (Sharma et al., 2013; Wang et al., 2009). Both ERα and AR splice variants have been identified (Zhang et al., 1996; reviewed in Dehm and Tindall, 2011). ERα and AR splice variants have been suggested to contribute to resistance to endocrine therapy in BCa and to recurrent therapy resistant PCa (Murphy et al., 1998; Kong et al., 2015).

    • Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression

      2013, Vitamins and Hormones
      Citation Excerpt :

      Several ERα mRNA splice variants have been identified in various normal tissues and in tumors, including breast cancer (Herynk & Fuqua, 2004). However, the expression of wild-type ERα was shown to be greater than that of the other spliced variants in 109 breast tumors analyzed (Zhang, Hilsenbeck, Fuqua, & Borg, 1996). Several studies have reported a role for certain splice variants in endocrine therapy resistance.

    View all citing articles on Scopus
    View full text